Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 7Myeloproliferative Disorders 3Recurrence 2Myelodysplastic Syndromes 2Hematologic Neoplasms 2Glioma 2Cholangiocarcinoma 2Pancreatic Ductal Adenocarcinoma 1Leukemia 1IDH1-Mutated Malignancies 1IDH1 Mutation Myeloid Neoplasms 1Chondrosarcoma 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × ivosidenib × Clear all
NCT02074839 2025-06-08

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Servier

Phase 1 Recruiting
291 enrolled 3 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04176393 2023-02-13

A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

CStone Pharmaceuticals

Phase 1 Completed
30 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡